Sector: Health Technology
Industry: Biotechnology
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Market Capitalization
115.522M
Total Shares Outstanding (MRQ)
54.236M
Net Debt (MRQ)
-56.821M
Total Assets (MRQ)
97.745M
Revenue per Employee (TTM)
9518.5185
Free Cash Flow (TTM)
-39.883M :(, but it's BIO and other indicators look good.
Phase 2-3 trials, FDA looking at turning decision from June that scared off investors.
Analyst upgrade to 7
Industry: Biotechnology
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Market Capitalization
115.522M
Total Shares Outstanding (MRQ)
54.236M
Net Debt (MRQ)
-56.821M
Total Assets (MRQ)
97.745M
Revenue per Employee (TTM)
9518.5185
Free Cash Flow (TTM)
-39.883M :(, but it's BIO and other indicators look good.
Phase 2-3 trials, FDA looking at turning decision from June that scared off investors.
Analyst upgrade to 7
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.